Though still not much closer to being accepted onto the AUT00063 trial, I have now received a "Participant Information Sheet". I do not know if any of this will be regarded as new but the information below is taken from the factsheet. Text in bold is directly quoted, text not in bold is my own comments or summarising of the info in the document.
* Reduced activity at certain sites in the brain (called "voltage-gated potassium channels") has been linked to hearing problems....AUT00063 is an experimental new medicine that has been developed to improve the action of these specific channels and so treat the brain component of these hearing problems.
* Subjects have taken the drug for only 21 days so far (presumably in Phase 1), whereas in this study (Phase 2a) subjects will take the drug for 28 days.
* Subjects up to the age of 45 years have received doses of up to 800mg daily...older subjects aged 61-75 years were given a maximum dose of 600mg daily (in Phase 1). This was to be more cautious in case elderly subjects were more sensitive to the drug. In the study, it did not appear that elderly subjects were more sensitive. Hence in this study (Phase 2a), all subjects at whatever age will be given 800mg daily.
* Safety will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.)
* People on antidepressants do not seem to be explicitly ruled out but "it would be preferable if brain acting medication was avoided while you were on the study".
* Caution is urged when driving or sunbathing. Exposure to "potentially damaging noise levels" is discouraged. Food or drink containing grapefruit will not be allowed. No explanation is given for the necessity of avoiding grapefruit.
* Participants will be required to visit the clinic 5 times. At the screening examination, they will undergo a complete phyical examination including ECG, blood and urine tests. "In some centres, some patients will undergo additional optional brain encephalography (EEG) and/or auditory brain response (ABR) tests."
* The most common side effects that were noted by participants (in Phase 1)...were mostly mild in nature and included headache, feeling a bit sleepy or tired, feeling a bit nauseous. At most, about 1 in 10 subjects felt these effects. Also, 4 study subjects out of 56 who received the study medicine, showed abnormal events on the heart rhythms which did not cause any symptoms. Heart experts reviewed the data and confirmed that these events were not a clinical worry and could not be proven to be related to the drug."
* Reduced activity at certain sites in the brain (called "voltage-gated potassium channels") has been linked to hearing problems....AUT00063 is an experimental new medicine that has been developed to improve the action of these specific channels and so treat the brain component of these hearing problems.
* Subjects have taken the drug for only 21 days so far (presumably in Phase 1), whereas in this study (Phase 2a) subjects will take the drug for 28 days.
* Subjects up to the age of 45 years have received doses of up to 800mg daily...older subjects aged 61-75 years were given a maximum dose of 600mg daily (in Phase 1). This was to be more cautious in case elderly subjects were more sensitive to the drug. In the study, it did not appear that elderly subjects were more sensitive. Hence in this study (Phase 2a), all subjects at whatever age will be given 800mg daily.
* Safety will be determined by looking at a number of assessments (physical examinations, blood sampling, hearing assessments, questionnaires, etc.)
* People on antidepressants do not seem to be explicitly ruled out but "it would be preferable if brain acting medication was avoided while you were on the study".
* Caution is urged when driving or sunbathing. Exposure to "potentially damaging noise levels" is discouraged. Food or drink containing grapefruit will not be allowed. No explanation is given for the necessity of avoiding grapefruit.
* Participants will be required to visit the clinic 5 times. At the screening examination, they will undergo a complete phyical examination including ECG, blood and urine tests. "In some centres, some patients will undergo additional optional brain encephalography (EEG) and/or auditory brain response (ABR) tests."
* The most common side effects that were noted by participants (in Phase 1)...were mostly mild in nature and included headache, feeling a bit sleepy or tired, feeling a bit nauseous. At most, about 1 in 10 subjects felt these effects. Also, 4 study subjects out of 56 who received the study medicine, showed abnormal events on the heart rhythms which did not cause any symptoms. Heart experts reviewed the data and confirmed that these events were not a clinical worry and could not be proven to be related to the drug."